Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.
3 reports, 2 independent
Updated Sep 8
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).Also in this story
- Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.
- Eli Lilly acquired Verve Therapeutics, advancing one-time treatments for high cardiovascular risk.
- Mineralys Therapeutics presented its clinical trial results at the American Heart Association sessions in Baltimore.
- Novartis gains exclusive rights to develop ARO-SNCA through a collaboration that validates Arrowhead's TRiM technology.
The entities involved
-
Ionis Pharmaceuticals
American pharmaceutical company
Nothing else this week.
-
Novartis
Swiss-American multinational pharmaceutical corporation